Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Selenoprotein W is a small selenoenzyme containing a selenocysteine residue at its active site, encoded by the SEPW1 gene. It is part of the SelWTH family with a thioredoxin-like fold, acting predominantly as a glutathione-dependent antioxidant protein and participating in redox regulation. SELENOW is highly expressed in muscle, heart, and brain. In muscle, SELENOW modulates proteostasis and is involved in the RAC1-mTOR signaling pathway, influencing protein synthesis and degradation. It also protects neurons from oxidative stress during development and has recently been identified as a key modulator of tau degradation and synaptic maintenance, implicating a role in Alzheimer’s disease and neurodegeneration. SELENOW’s expression is tightly regulated by selenium availability; deficiency is associated with certain diseases, including Keshan disease and potentially neurodegenerative pathologies.
For selenium or selenium-containing compounds: - Upregulates SELENOW expression, exerting antioxidant effects. - Promotes tau clearance via ubiquitin-proteasome pathway (in neurodegeneration). - Supports muscle proteostasis via SELENOW-RAC1-mTOR signaling cascade.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Selenoprotein W (SELENOW).